The Center for Biomedical Engineering and Science OPEN HOUSE November 21, 2014 CBES Administrative Office University of North Carolina at Charlotte 224 Duke Centennial Hall 9201 University City Blvd. Charlotte, NC 28223 Phone: 704-687-8608 Fax: 704-687-8607 E-mail: [email protected]CBES OPEN HOUSE Friday, November 21, 2014 2:00pm—5:00pm Woodward Hall, Room 130 CBES Leadership Team Dr. Charles Y. Lee, CBES Director Michele Wallace, CBES Business Manager Focus Area Leaders Dr. Mark Clemens, Medical Therapies and Technologies Dr. Don Jacobs, Molecular Engineering and Design Dr. Nigel Zheng, Biomechanics and Mobility Research AGENDA I. Open Network & Refreshments II. Welcome………………………………..Dr. Charles Lee CBES Director III. Oral Presentations………..Dr. Chandra Williams IV. Tour of Vivarium and IVIS Imaging System V. Tour of Investigators’ Labs and Woodward Equipment VI. Networking CBES Mission To foster advancements in biomedicine through interdisciplinary and translational research at the interface of biomedical science and engineering
2
Embed
CBES OPEN HOUSE - NC Biotech · 2014. 11. 21. · E-mail: [email protected] CBES OPEN HOUSE Friday, November 21, 2014 2:00pm—5:00pm Woodward Hall, Room 130 CBES Leadership Team Dr.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Dr. Cho's expertise is the development of bioengineered microenvironments and nanobiosensors. He worked as a research fellow at Harvard Medical School/Mass General Hospital to implement his expertise on brain-on chips for the study of Alzheimer's disease and neurovas-cular diseases. His current research focuses on cells chips to enable new discoveries in the areas of neurosci-ences and cancer biology, innovative mechanical com-
ponents involving multiple physics, and portable platforms for healthcare diagnostics and environmental sustainability. For more information regarding Dr. Cho's research please visit his webpage https://coefs.uncc.edu/hcho17/
Dr. Clemen’s lab specializes in the regulation of liver microcirculation: Role of stress-inducible vasoactive mediators (endothelin, nitric oxide synthase, hydrogen sulfide, sonic hedgehog, heme oxygenase) in altering vascular responsiveness in the liver following oxidative or inflammatory stress. Mechanisms of control of sinusoid perfusion by hepatic stellate cells, especially related to components of phenotypic transformation in response to
injury. His research is also centered around the hepatic metabolic re-sponse to infection. Mechanisms of altered carbohydrate metabolism during sepsis, especially related to differentiation between inflammation-induced changes in gene expression and perfusion supply/demand ratio as mediators of decreased gluconeogenesis. The application of imaging techniques to biological research is another important part of Dr. Clemen’s research. It uses the In vivo video microscopy for study of liver microcir-culation and an application of quantitative fluorescence techniques in the monitoring of cellular processes in intact organs or in vivo. Engineered liver support systems: Bioengineering Research Partnership.
Dr. Dre au’s lab interests are centered on the biology of tumor metastasis. Specifically, we study tumor cell migra-tion, the influences of the tumor microenvironment and the rate of metastasis. We seek to better understand the key steps associated in the cancer progression and devel-op diagnostic and prognostic tools to improve patient care. To successfully achieve the long-term objectives, my research team is involved in ongoing collaborative and
multidisciplinary efforts involving clinicians, biologists and engineers.
Dr. El-Ghannam specializes in synthesis and characteri-zation of biomaterials for drug delivery and tissue reconstruction. His lab creates resorbable scaffolds for tissue reconstruction and to enable in vivo drug delivery to signal cells. The research activities of El-Ghannam’s lab addresses problems related to treatment of breast and liver cancer and bone infection. He routinely per-forms biocompatibility tests, drug release kinetics,
assessment of therapeutic effects and cell function and engineering surfaces of biomaterials to stimulate cell function and tissue formation.
Dr. Mukherjee’s translational research focuses on the understanding the basic oncogenic pathways of tumor progression and metastasis associated MUC1 as well as they development of novel cancer vaccines that activate the existing immune response against the “foreign” tumor-specific proteins. The goal is to develop immune memory against the cancer, so that if the cancer recurs, it will be recognized immediately as foreign and be reject-
ed. In particular, her lab focuses on pancreatic cancer and metastatic breast cancer, both of which are fatal. Since preclinical studies must precede clinical trials, we have developed oncogenic transgenic mouse models that appropriately mimic the human disease and expresses human proteins. Tumors develop spontaneously within the pancreas or the breast, thus receiving appropriate hormonal and molecular signals. Similar to human disease, the tumors arise in an immune-competent and immune-tolerant host. Tumor-Site Directed Therapy: Another grave challenge for cancer therapeutics has been the systemic toxicity, and the failure of the therapeutics to reach the tumor site. Therefore, my labora-tory is designing tumor-targeting antibody that is fused to some of the promising therapeutic agents. The antibody only recognizes tumor cells in the primary site and in the metastatic lesions without targeting normal cells. This technology has huge clinical relevance. It may have the potential of aiding early detection and diagnosis. Ultimately, this antibody has the potential as a site-directed therapeutic delivery system (with either drugs or radio-conjugates) in patients with metastatic cancers.